Stockholm Stock Exchange | Mid Cap
Calliditas
+138.99%
Latest
+83.65%
3 months
Bryan GarnierCarnegieSEBKepler CheuvreuxPareto SecuritiesCiti Investment ResearchKempenSEB Equities

Price Targets For Calliditas

AnalystPrice TargetDateUpside
Bryan Garnier190 SEKSep 21
+138.99%
Carnegie133 SEKAug 19
SEB115 SEKJul 27
Kepler Cheuvreux140 SEKJun 16
Pareto Securities300 SEKJun 2
Citi Investment Research384 SEKDec -21
Kempen320 SEKDec -21
SEB Equities75 SEKNov -21

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas